Brinker Capital Investments’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Brinker Capital Investments’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,167	Closed	-$238K	–	1417
2022 Q2	$238K	Buy	+3,167	New	+$141K	﹤0.01%	1248
2021 Q4	–	Sell	-2,850	Closed	-$222K	–	1452
2021 Q3	$222K	Hold	2,850	–	–	﹤0.01%	1229
2021 Q2	$222K	Buy	2,850 +129	+5%	+$9.53K	﹤0.01%	1281
2021 Q1	$257K	Sell	2,721 -1,043	-28%	-$124K	﹤0.01%	1091
2020 Q4	$459K	Buy	+3,764	New	+$412K	0.01%	857

Brinker Capital Investments's TPTX Position: Q3 2022 in Review

Brinker Capital Investments sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 3,167 shares — an estimated $238K sold.

Brinker Capital Investments first reported a position in TPTX in Q4 2020 and held it in 5 quarters. The position peaked at $459K in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Brinker Capital Investments reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Brinker Capital Investments sold 3,167 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $238K.
Brinker Capital Investments first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Brinker Capital Investments's Turning Point Therapeutics, Inc. Common Stock position peaked at $459K in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Brinker Capital Investments's 13F filing for Q3 2022, filed 1 Nov 2022.